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immunotherapy with anti-inflammatory
treatment in a transgenic mouse model
of multiple system atrophy
Elvira Valera1 , Brian Spencer1, Jerel A. Fields1, Ivy Trinh1, Anthony Adame1, Michael Mante1, Edward Rockenstein1,
Paula Desplats1,2 and Eliezer Masliah1,2*Abstract
Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by the pathological accumulation
of alpha-synuclein (α-syn) in oligodendrocytes. Therapeutic efforts to stop or delay the progression of MSA have
yielded suboptimal results in clinical trials, and there are no efficient treatments currently available for MSA patients.
We hypothesize that combining therapies targeting different aspects of the disease may lead to better clinical
outcomes. To test this hypothesis, we combined the use of a single-chain antibody targeting α-syn modified for
improved central nervous system penetration (CD5-D5) with an unconventional anti-inflammatory treatment
(lenalidomide) in the myelin basic protein (MBP)-α-syn transgenic mouse model of MSA. While the use of either
CD5-D5 or lenalidomide alone had positive effects on neuroinflammation and/or α-syn accumulation in this
mouse model of MSA, the combination of both approaches yielded better results than each single treatment.
The combined treatment reduced astrogliosis, microgliosis, soluble and aggregated α-syn levels, and partially
improved behavioral deficits in MBP-α-syn transgenic mice. These effects were associated with an activation of
the Akt signaling pathway, which may mediate cytoprotective effects downstream tumor necrosis factor alpha
(TNFα). These results suggest that a strategic combination of treatments may improve the therapeutic outcome
in trials for MSA and related neurodegenerative disorders.
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NeuroinflammationIntroduction
Multiple system atrophy (MSA) is a rapidly progressive
and fatal neurodegenerative disease characterized by par-
kinsonism, dysautonomia [5, 56], and accumulation of the
protein alpha-synuclein (α-syn) within oligodendroglial
cells in the form of glial cytoplasmic inclusions [16, 19]
leading to neuroinflammation, demyelination and neuro-
degeneration [15, 25, 43, 47, 50, 57]. The lack of response
to levodopa and the extensive accumulation of α-syn* Correspondence: emasliah@ucsd.edu
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(http://creativecommons.org/publicdomain/zewithin oligodendrocytes differentiates MSA from other
synucleinopathies [6, 55]. MSA is an orphan neurodegen-
erative disorder with no effective disease-modifying treat-
ment, and recent clinical trials of MSA therapies have
failed to meet primary endpoints [7, 23, 30, 35]. These
negative results were probably associated with the late
diagnosis of this disorder, and treatments being initiated
when α-syn accumulation and neuroinflammation are
already widespread.
Regarding potential therapies for MSA, some anti-
inflammatory treatments have shown promise at the
preclinical level [42, 46, 50], and therapies aimed at
reducing neuroinflammation are currently being tested
in clinical trials (Clinical trial identifiers NCT02388295,
NCT02315027). We have recently explored the use ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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as therapeutics in animal models of synucleinopathy. We
observed that the antidepressants fluoxetine, olanzapine
and amitriptyline not only ameliorate neuroinflamma-
tion, but also reduce the accumulation of α-syn in the
Myelin Basic Protein (MBP)-α-syn transgenic (tg) mouse
model of MSA [50]. Moreover, another unconventional
anti-inflammatory, the anticancer drug and immunomod-
ulatory compound lenalidomide, was able to effectively re-
duce microgliosis and the expression of pro-inflammatory
cytokines in an animal model of Parkinson’s disease (PD)
[48], a disorder also characterized by the accumulation of
α-syn. Lenalidomide is a small thalidomide derivative with
anti-angiogenic and immunomodulatory activity, that has
shown therapeutic effects in multiple myeloma [3, 31, 45]
and in animal models of Amyotrophic lateral sclerosis
[28, 44]. Its mechanisms of action are multiple, primar-
ily involving T cell co-stimulation [14, 18, 59], increased
NK cell proliferation and function [18, 59], and inhib-
ition of the production of TNFα [13, 31, 59] and other
proinflammatory cytokines [4]. We selected lenalido-
mide for this study because preliminary reports showed
that this compound is also effective at reducing neuro-
inflammation in the tg mouse model used in this study
([49], and unpublished data). Moreover, these results
suggest that the repurposing of FDA-approved com-
pounds may speed up the search for an effective ther-
apy for MSA.
Immunotherapy has also shown promise for treating
neurodegenerative disorders; moreover, active immuno-
therapeutic approaches are under consideration for the
treatment of MSA patients (Clinical trial identifier
NCT02270489). Regarding passive immunotherapy, we
have recently developed a single-chain antibody against
α-syn that is conjugated to the LDL receptor-binding
domain of apolipoprotein B (ApoB), which allows the
antibody to readily cross the blood-brain barrier [40].
Systemic expression of this antibody effectively reduced
neuronal α-syn accumulation in a tg mouse model of
synucleinopathy [40]. Moreover, the modified single-
chain antibody showed enhanced brain penetration and
was imported into neuronal cells through the endosomal
sorting complex required for transport (ESCRT) path-
way, leading to lysosomal degradation of α-syn aggre-
gates. Further analysis showed that this antibody was
also effective at ameliorating neurodegenerative path-
ology, neuroinflammation and behavioral deficits ob-
served in the mouse model of synucleinopathy [40].
These exciting results reported by others and ourselves
led us to hypothesize that combining FDA-approved im-
munomodulatory compounds with our successful immuno-
therapeutic strategy might be beneficial for the treatment of
synucleinopathies. The rationale is that combining treat-
ments targeting different aspects of the disease (i.e.neuroinflammation plusα-syn accumulation) may enhance
the beneficial effects of single therapies. Therefore, the goal
of the current study is to test in vivo the feasibility and effi-
cacy of a combination of α-syn immunotherapy and anti-
inflammatory treatment for MSA and related disorders.
Materials and methods
Animal model and treatments
Mice expressing human α-syn under the control of the
MBP promoter (MBP-α-syn tg, line 1) were generated as
previously described [38]. MBP-α-syn tg mice develop
progressive accumulation of α-syn inclusions in oligo-
dendrocytes along the axonal tracts in the brainstem,
basal ganglia, cerebellum, corpus callosum, and neocor-
tex, leading to neurodegeneration in the neocortex and
to loss of dopaminergic fibers in the basal ganglia. Non-
tg and MBP-α-syn tg mice (n = 12–14 per condition and
genotype) were administered by intraperitoneal injection
of a lentiviral construct expressing the single-chain anti-
body CD5-D5 linked to ApoB sequence (LV-CD5-D5-
ApoB), or LV-control (100 μl/mouse, 1 × 109 transducing
units). As previously described [8, 40], the anti-
oligomeric α-syn single-chain antibody (D5) cDNA was
amplified by PCR and cloned into the third-generation
self-inactivating lentivirus vector plasmid [41] with the
CMV promoter driving expression. D5 is linked to the
secretory signal from the human CD5 gene [17] and to
the LDL receptor-binding domain from apolipoprotein B
(apoB) [40]. The construct also includes a V5 tag for
immunodetection (Additional file 1).
One week after injection, mice were treated with lena-
lidomide (100 mg/kg) or vehicle (0.5% methocellulose)
daily for 4 weeks (n = 6–7 per condition and genotype).
Fresh vehicle or lenalidomide preparations were admin-
istered via gavage in a 5 ml/kg volume. All mice were
between 10 and 11 months of age by the end of the
study. All experiments were carried out in accordance
with the guidelines set by the NIH regarding the care
and use of animals for experimental procedures. All ani-
mal procedures were approved by the UCSD Institu-
tional Animal Care and Use Committee.
Behavioral analyses
The behavioral assessment of the animals was performed
using open field 1 week before endpoint. As previously de-
scribed [34], animals were evaluated for 10 min for three
consecutive days, given a 2-day dishabituation period,
followed by a fourth and final trial. Context-dependent
learning was collected using a Kinder SmartFrame Cage
Rack Station activity monitor system (Kinder Scientific),
in 3-dimentional space using a 7x15 beam configuration.
Data collection began when an animal was placed in the
test chamber. Total activity and rearing (i.e. standing on
rear limbs) were calculated as total beam breaks in
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of time spent in the periphery.
Immunohistochemistry
Mice were sacrificed under anesthesia following NIH
guidelines for the humane treatment of animals, and
brains were removed. The right hemibrain was fixed by
immersion in 4% paraformaldehyde in PBS pH 7.4 and
serially sectioned at 40 μm with a Vibratome apparatus
(Leica) for subsequent analysis. The left hemibrain was
stored at −80 °C for biochemical analysis, and further
processed for either quantitative real-time polymerase
chain reaction (qPCR) or protein analysis.
Vibratome sections were immunolabeled overnight
with antibodies against α-syn (Sigma, 1:250), Glial fibril-
lary acidic protein (GFAP) (Millipore, 1:500), Iba1
(Wako, 1:2000) or MAP2 (Millipore, 1:500), followed by
incubation with species-appropriate secondary anti-
bodies (Vector Laboratories). Sections were reacted with
3,3’-diaminobenzidine (Vector Laboratories) and imaged
on an Olympus BX41 microscope. A minimum of 100
cells were counted per animal, and cell counts are
expressed as the average number of positive cells per
field (230 μm x 184 μm). Quantification of GFAP and
Iba1 staining was performed by obtaining optical density
measurements using the Image Quant 1.43 program
(NIH) and corrected against background signal levels.
Immunoblotting and ELISA assay
Protein homogenates were prepared from the mouse
posterior hemibrain. Briefly, frozen samples were soni-
cated in homogenization buffer (HEPES 1 mM, benza-
midine 5 mM, 2-mercaptoethanol 2 mM, EDTA 3 mM,
MgSO4 0.5 mM, NaN3 0.05%, protease inhibitor cocktail
set III 1:100, phosphatase inhibitor cocktail set II 1:100)
and ultracentrifuged at 100,000 rpm for 1 h to obtain
cytosolic (soluble) and particulate (insoluble, membrane-
bound) fractions. 20 μg of protein from the cytosolic or
particulate fractions were loaded onto 4–12% Bis-Tris
SDS-PAGE gels (Invitrogen) and transferred onto Immo-
bilon membranes. After overnight incubation with anti-
bodies against total α-syn (Millipore), phospho- and
total p38 (Abcam, Cell Signaling Technologies), phos-
pho- and total Akt (Cell Signaling Technologies), phos-
pho- and total ERK1/2 (Cell Signaling Technologies),
tumor necrosis α (TNFα) (Santa Cruz), MBP (BioRad),
CNPase (Sigma) or Olig2 (IBL International), mem-
branes were incubated in HRP-linked secondary anti-
body (American Qualex), reacted with ECL Western
blotting substrate (Perkin Elmer) and developed in a
VersaDoc gel-imaging system (BioRad). An antibody
against β-actin was used as loading control. Immuno-
blotting images were analyzed using Quantity One
software (BioRad).Levels of human α-syn were determined in the cyto-
solic fraction of mouse brain homogenates by an ELISA
assay (Invitrogen) according to the manufacturer’s
protocol. 2.5 μg of protein were used per animal per re-
action, and concentration of α-syn was calculated by ex-
trapolating from a human α-syn standard curve.
RNA isolation and real time PCR
Total RNA was extracted from the mouse anterior hemi-
brain using a Qiagen RNeasy kit and following the
instructions of the manufacturer. 0.5 μg of RNA per
sample were used for reverse transcription to cDNA
using a High capacity cDNA reverse transcription kit
(Applied Biosystems). qPCR was performed using Taq-
Man Fast Advanced Master Mix and the appropriate
TaqMan primers (Life Technologies). qPCR reactions
were run in an StepOnePlus Real-Time PCR system and
ΔΔCt calculations [36] were made using StepOne soft-
ware (Applied Biosystems).
Statistical analysis
Values are expressed as average ± standard error of the
mean (SEM). To determine the statistical significance
we used one-way analysis of variance (ANOVA) with
Dunnett post-hoc test when comparing to the control
condition. Additional comparisons were done using
Tukey post hoc test. The differences were considered to
be significant if p values were less than 0.05.
Results
Combined treatment with lenalidomide and CD5-D5
ameliorates neuroinflammation in the MBP-α-syn
transgenic mouse model of MSA
The pathological accumulation of α-syn within oligoden-
drocytes observed in MSA brains, and reproduced in tg
mouse models of MSA, is typically associated with an in-
crease in neuroinflammation markers [52]. The astro-
gliosis and microgliosis present in MSA brains may have
deleterious effects such as potentiating neurodegenera-
tion and α-syn accumulation. Therefore, reducing neu-
roinflammation may represent a promising therapeutic
goal in MSA patients. We have recently explored the use
of anti-inflammatory molecules in MSA models [50],
and have analyzed the effects of lenalidomide in a mouse
model of PD [48]. Moreover, passive immunization of α-
syn tg mice with the single-chain anti-α-syn antibody
CD5-D5 also reduced neuroinflammation [40].
In the current study we explored the neuroprotective
effects of the combined treatment of lenalidomide and
CD5-D5 in the MBP-α-syn tg mouse model of MSA.
Immunohistochemistry results showed that the combined
treatment reduced astrogliosis in the corpus callosum and
striatum, as measured by GFAP immunostaining (Fig. 1).
Specifically, the optical density of the GFAP signal was
Fig. 1 Combined treatment reduces astrogliosis and microgliosis in MBP-α-syn transgenic mice. a-c Representative images of GFAP immunostaining
and optical density quantification in neocortex (a), corpus callosum (b) and striatum (c) of non-tg and MBP-α-syn tg mice treated with LV-control or
LV-CD5-D5-ApoB, and vehicle or lenalidomide. d-f Representative images of Iba1 immunostaining and optical density quantification in neocortex (d),
corpus callosum (e) and striatum (f) of non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. Results
are presented as average ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 when comparing vehicle/LV-control-treated non-tg mice to vehicle/
LV-control-treated tg mice. # p < 0.05, ## p < 0.01 and ### p < 0.001 when comparing vehicle/LV-control-treated tg mice to single or multi-treated
tg mice. Scale bar = 25 μm
Valera et al. Acta Neuropathologica Communications  (2017) 5:2 Page 4 of 10increased by 60 and 70% in the corpus callosum and
striatum, respectively, of the tg mice compared to non-tg
controls; lenalidomide and CD5-D5 treatment returned
GFAP signal to that of control mice (Fig. 1b, c). This effect
seems to be mostly due to the anti-inflammatory effect of
lenalidomide, as it can be deduced by comparing to the
lenalidomide-only treatment. Moreover, the optical dens-
ity of the Iba1 signal was increased by 30 and 100% in the
corpus callosum and striatum, respectively, of the tg mice
compared to non-tg controls; lenalidomide and CD5-D5
treatment returned Iba1 signal to that of control mice
(Fig. 1b, c). Both lenalidomide treatment and immuno-
therapy had a similar inhibitory effect on microgliosis, and
the combined treatment showed no synergistic effect. A
more detailed analysis of microglial morphology revealed
that striatal Iba1-positive cells from MBP-α-syn tg mice
show increased ramification, and that both single and
combined treatments reduced the number of branches
per cell (Additional file 2), mirroring optical density re-
sults. Moreover, treatment with lenalidomide and/or
CD5-D5 increased microglial cell soma diameter in the
striatum of tg animals [54], suggesting a shift in microglial
polarization towards phagocytic state as a consequence of
the immunotherapy [2, 20]. Finally, additional analysis of
neuronal dendritic arborization using MAP2 immuno-
staining revealed a significant increase in striatal dendritic
density with lenalidomide or CD5-D5 treatment, and a
surge in the number of dendritic ramifications with both
single and combined treatments (Additional file 3).It has been postulated that reducing neuroinflammation
may prevent the downstream toxic effects of α-syn. Our
results suggest that lenalidomide is effective at reducing
neuroinflammation in a tg mouse model of MSA, and
that its combination with an anti-α-syn approach does
not have adverse inflammatory effects in mice.
Combined treatment with lenalidomide and CD5-D5
reduces α-syn accumulation in the MBP-α-syn transgenic
mouse model of MSA
Immunotherapy against α-syn has been effective at redu-
cing α-syn accumulation in different models of synuclei-
nopathy, and it is currently under investigation for its
efficacy in human patients. We measured the accumula-
tion of α-syn by immunohistochemistry, immunoblot
and ELISA in the brain of MBP-α-syn tg mice treated
with lenalidomide and/or CD5-D5 (Fig. 2). The com-
bined treatment of lenalidomide and CD5-D5 signifi-
cantly reduced the accumulation of α-syn in all brain
areas analyzed by 75–80% (Fig. 2a-c). This effect was 2–3
times stronger than treatment with CD5-D5 alone,
suggesting that combination with lenalidomide may po-
tentiate or trigger additional clearance mechanisms. This
reduction not only affected α-syn aggregates (insoluble α-
syn), as the combined treatment also reduced soluble α-
syn measured by immunoblot and ELISA (Fig. 2d, f ).
These results further support the use of this type of
combined treatment, as it improves the results obtained
by single therapies, which are by themselves less efficient.
Fig. 2 Combined treatment reduces α-syn accumulation in MBP-α-syn transgenic mice. a-c Representative images of α-syn immunostaining and
cell counts in neocortex (a), corpus callosum (b) and striatum (c) of non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB,
and vehicle or lenalidomide. d Immunoblot and densitometric analysis of α-syn in the soluble fraction of protein extracts from non-tg and MBP-α-syn
tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. Significant results of three mice per group are shown. e Immunoblot
and densitometric analysis of α-syn in the insoluble fraction of protein extracts from non-tg and MBP-α-syn tg mice treated with LV-control or
LV-CD5-D5-ApoB, and vehicle or lenalidomide. Significant results of three mice per group are shown. f ELISA analysis of human α-syn levels in
the soluble fraction of protein extracts from non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or
lenalidomide. Results are presented as average ± SEM. *** p < 0.001 when comparing vehicle/LV-control-treated non-tg mice to vehicle/LV-control-
treated tg mice. # p < 0.05, ## p < 0.01 and ### p < 0.001 when comparing vehicle/LV-control-treated tg mice to single or multi-treated tg mice.
Scale bar = 25 μm
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may be altering the number of mature oligodendrocytes
instead of reducing α-syn accumulation. Preliminary
tests with lenalidomide in the MBP-α-syn tg mouse
model revealed that this compound did not alter the
number of mature oligodendrocytes as measured by
p25α immunostaining (data not shown). MBP and
CNPase protein levels were not significantly reduced in
MBP-α-syn tg animals (Additional file 4), consistent with
the fact that the tg mouse line used in this study shows
less myelin pathology than higher α-syn expressor lines
[38]. Interestingly, the levels of early oligodendroglial
precursor cell (OPC) marker Olig2 showed a trend to the
increase in tg animals (Additional file 4), in line with pre-
vious studies reporting an increase in OPC numbers in
this mouse model, and a blockage in OPC differentiation
[9, 26]. Neither of the treatments had a significant effect
on oligodendrocyte marker levels (Additional file 4), sug-
gesting that the changes observed in α-syn accumulation
were likely due to the clearance of intracellular aggregates.
Combined treatment with lenalidomide and CD5-D5
modulates TNFα expression and activates Akt signaling
in the MBP-α-syn transgenic mouse model of MSA
To determine the effect of combining lenalidomide and
immunotherapy againstα-syn on the inflammatory re-
sponse, we analyzed the expression of the cytokineTNFα in the brain of MBP-α-syn tg mice treated with
lenalidomide and/or CD5-D5 (Fig. 3a, b). Release of
TNFα by microglia has been traditionally associated to
neuroinflammation, and it mediates pro-inflammatory
cascades associated to cytotoxicity [12, 32]. Lenalido-
mide was originally developed as an anti-TNFα mol-
ecule, and has been shown to reduce both TNFα mRNA
and protein levels [31, 59]. We observed that levels of
soluble TNFα were reduced approximately 40% in the
mouse brain with lenalidomide treatment (Fig. 3a, b). A
trend for the increase of soluble TNFα in the brain of tg
animals treated with either CD5-D5 or combined
treatment was also observed (Fig. 3a, b), indicating that
antibody treatment counteracts the TNFα-reducing ef-
fects of lenalidomide in this mouse model. Levels of
membrane-bound (insoluble) TNFα were significantly
elevated by 50% in MBP-α-syn tg mice, and were not al-
tered by any of the treatments (Fig. 3a, b). These results
suggest that even though antibody treatment appears to
be neutralizing the anti-TNFα effects of lenalidomide,
the neuropathological analysis showing reduced neuroin-
flammation with the combined treatment (Fig. 1) in-
dicates that this modulation of TNFα expression does
not translate into reduced anti-inflammatory effects.
Furthermore, it is possible that a mild activation of
microglia elicited by immunotherapy may be behind
these changes.
Fig. 3 Combined treatment modulates TNFα expression and Akt signaling in MBP-α-syn transgenic mice. a Immunoblot analysis of the levels of
soluble and insoluble (membrane-bound) TNFα in non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide.
Significant results of three mice per group are shown. b Densitometric analysis of the levels of soluble and insoluble (membrane-bound) TNFα in non-tg
and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. c Immunoblot and densitometric analysis of
phospho- and total Akt and phospho- and total ERK1/2 in the soluble fraction of protein extracts from non-tg and MBP-α-syn tg mice treated
with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. Significant results of three mice per group are shown. d Densitometric
analysis of the levels of the phospho- and total Akt, and phospho- and total ERK1/2 immunoreactive bands, normalized by actin levels and
expressed as phospho/total ratio. Results are presented as average ± SEM. ** p < 0.01 when comparing vehicle/LV-control-treated non-tg mice
to vehicle/LV-control-treated tg mice. ## p < 0.01 when comparing vehicle/LV-control-treated non-tg mice to multi-treated non-tg mice, or
vehicle/LV-control-treated tg mice to single or multi-treated tg mice
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ciated to p38, JNK and ERK1/2 (MAPKs) downstream
pathways [53]. However, in certain cases TNFα can also
activate cytoprotective signaling, that may be associated
to Akt activation [11]. Immunoblot analysis confirmed a
significant reduction in phosphorylated (activated) Akt
in MBP-α-syn tg animals compared with non-tg litter-
mates (Fig. 3c, d). Both lenalidomide and CD5-D5 sig-
nificantly increased phospho-Akt in tg animals, with the
combined treatment achieving the higher Akt activation
(Fig. 3c, d). However, all of the treatments showed a trend
for a reduction in ERK1/2 phosphorylation (Fig. 3c, d).
Levels of phosphorylated p38 were not increased by any of
the treatments (not shown). These results, together with
the neuropathology data, suggest that the activation of
Akt signaling and the reduction of ERK1/2 signaling may
coordinately achieve a cytoprotective effect in this tg
model. Moreover, these results further confirm the anti-
inflammatory potential of the combined treatment at the
molecular level.Combined treatment with lenalidomide and CD5-D5
modulates behavioral changes in the MBP-α-syn
transgenic mouse model of MSA
To determine if lenalidomide and CD5-D5 reverses be-
havioral deficits, animals were also analyzed using the
open field monitoring system (Fig. 4). While MBP-α-
syn tg animals showed no changes in hyperactivity
phenotype when compared to non-tg littermates, we
did observe a significant decrease in rearing and a trend
to reduction of total activity with the combined treat-
ment (Fig. 4a, b), suggesting that the treatment may
have hyperactivity-reducing effects. Thigmotaxis, a
measure of anxiety, was not significantly altered with
any of the treatments (Fig. 4c). The behavioral modifi-
cation achieved with the treatment seemed to be mostly
due to CD5-D5 treatment. More research is needed in
models with stronger hyperactivity phenotype to
further determine the full extent of behavioral improve-
ments that could be induced by the combined
treatment.
Fig. 4 Combined treatment modulates behavioral changes in MBP-α-syn transgenic mice. Non-tg and tg animals treated with LV-control or
LV-CD5-D5-ApoB, and vehicle or lenalidomide were analyzed in the open field test. a Total activity, measured as total beam breaks. b Rearing,
measured as total beam breaks. c Thigmotaxis, measured as the percentage of time spent in the periphery. Results are presented as average ± SEM.
# p < 0.05 when comparing vehicle/LV-control-treated tg mice to single or multi-treated tg mice
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Effective treatments for orphan neurodegenerative disor-
ders like MSA are sorely needed. Unfortunately for MSA
patients, several promising therapeutic compounds re-
cently failed in clinical trials, and identifying novel inter-
ventions is challenging the traditional process of drug
discovery. In the current study we investigate the
therapeutic efficacy of combining an unconventional
anti-inflammatory therapy (lenalidomide) with an α-syn-
reducing immunotherapeutic approach (CD5-D5 single-
chain antibody) in a novel tg mouse model for MSAFig. 5 Proposed mechanism of action of the combined treatment with len
MSA, oligodendrocytes produce high levels of α-syn, leading to the pro-inf
the mechanism of action of lenalidomide and LV-CD5-D5-ApoB in the MBP-α
(Len) and LV-CD5-D5-ApoB (D5) reduces oligodendroglial α-syn accumulation
and activates the cytoprotective Akt signaling. Immunotherapy with LV-CD5-D
microglial cells and reducing its incorporation into astroglial cells. The combin
be linked to the observed inhibition of ERK1/2 in favor of Akt signalingpathogenesis. Interestingly, we observed that the com-
bined treatment achieves better results than each treat-
ment alone in a tg mouse model of MSA. Together,
lenalidomide and CD5-D5 significantly reduced astro-
gliosis, microgliosis, and soluble and insoluble α-syn ac-
cumulation (results are summarized in Fig. 5). The
combined treatment increased the activation of the Akt
signaling pathway, that has been previously associated
with cytoprotective effects in the brain. Finally, the treat-
ment also ameliorated some behavioral measurements in
this tg mouse model. Similar to successful treatmentalidomide and CD5-D5. In the MBP-α-syn transgenic mouse model of
lammatory activation of microglia and astroglia. The diagram shows
-syn transgenic mouse brain. The combined treatment with lenalidomide
, modulates astroglial activation, regulates the expression of cytokines,
5-ApoB may also target extracellular α-syn, promoting its uptake by
ed treatment also increases the expression of TNFα mRNA, which could
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sults indicate that combining two or more compatible
therapies might have increased therapeutic potential
when compared to using single therapies for the treat-
ment of neurodegenerative disorders.
For the first time, we show that combining lenalido-
mide and an anti-α-syn antibody with enhanced penetra-
tion to the CNS achieves better results than treatment
with either one alone in a tg mouse model of MSA. This
is the case of the reduction observed in the number of
α-syn-positive cells in all brain areas analyzed, and the
reduction in rearing in MBP-α-syn tg mice treated with
the combination of both therapies. In other cases, the ef-
fect of the combined treatment could be attributed to
one of the treatments (Fig. 5). Interestingly, we did not
observe that the combined treatment worsened any of
the parameters analyzed, and it always achieved equal or
better outcomes than either of the single treatments.
Lenalidomide and CD5-D5 modulate both shared and
treatment-specific pathways in glial cells. While lenalido-
mide is a potent anti-inflammatory [28, 48], CD5-D5
seems to act through stimulation of brain cells to uptake
and clear α-syn [40], achieving a reduction in neuroin-
flammation. Alternatively, CD5-D5 may reduce neuroin-
flammation through an indirect mechanism downstream
of the activation of α-syn clearance mechanisms. Inter-
estingly, we observed greater reduction in α-syn levels
with the combined treatment than with each treatment
alone, supporting the idea of combined treatments as a
better alternative for MSA and other synucleinopathies.
Interestingly, we also observed a reduction in α-syn
accumulation with lenalidomide treatment in the MBP-
α-syn tg animals, while we previously failed to observe
such reduction in the mThy1-α-syn tg mouse model of
PD [48]. This discrepancy may be due to the intrinsic
differences between these two models of synucleinopa-
thy. The mThy1-α-syn tg mice express human α-syn in
neurons [33] while MBP-α-syn tg express it in oligoden-
drocytes (glia) [38], which may react differently to lenali-
domide treatment. It is also possible that the reduction
in α-syn accumulation achieved by lenalidomide is an in-
direct effect of its modulatory effect on the phagocytic
activity of microglial cells [22, 48]. Finally, we cannot
rule out the possibility of lenalidomide altering α-syn
propagation, as we have observed before with other
anti-inflammatory treatments such as the antidepres-
sant fluoxetine [50].
It is important to consider that lenalidomide and other
anti-inflammatory compounds modulate the immune sys-
tem, and this effect should be taken into consideration
when simultaneously modulating microglial responses
with an anti-inflammatory and stimulating microglia with
an immunotherapeutic treatment. To prevent an inter-
action between the treatments that may neutralize someof the desired effects, we administered immunotherapy
1 week before lenalidomide treatment. Moreover, the dual
effects of lenalidomide and CD5-D5 in microglial acti-
vation may explain the signaling results observed.
Lenalidomide was initially developed as an anti-TNFα
molecule that effectively reduces mRNA and protein
levels of TNFα in cancer models [31]. Lenalidomide
alone reduced the levels of soluble TNFαmeasured in
total RNA from whole brain extracts, however the
combined treatment failed to induce a reduction in the
levels of soluble TNFα. Such disparities highlight the
complex regulation of cytokine expression in the brain,
and in particular that achieved by combining drugs
that may have complementary effects on immune cells.
We hypothesize that the effect observed in TNFα
levels could be due to a mild activation of microglia by
the immunotherapy to stimulate α-syn clearance, an
effect that has been previously observed in other im-
munotherapy studies [24, 27, 37]. Importantly, the de-
tected changes in TNFα levels were not associated
with increased astrogliosis or microgliosis, as demon-
strated in Fig. 1.
TNFα has been traditionally associated with pro-
inflammatory changes in the diseased brain [1, 39], how-
ever several studies have suggested that TNFα may also
play an anti-inflammatory role [10, 21]. Interaction of
TNFα with TNFR1 has been associated with activation
of p38, JNK and ERK1/2 leading to inflammation and
cytotoxicity [51], while binding to TNFR2 is associated
with the activation of signaling cascades that promote
cytoprotection [51]. Furthermore, TNFR2 stimulation in
microglia regulates the expression of genes involved in
immune processes, including molecules with anti-
inflammatory and neuroprotective function [51]. While
activation of Akt signaling can be pro-inflammatory in
some cases, the activation of the Akt signaling pathway
may improve cell survival depending on the receptor up-
stream Akt activation [29, 58]. Further research will be
needed to elucidate how the combined treatment, but
not each treatment separately, is able to activate cyto-
protective pathways.
Conclusions
In conclusion, our results show that the combination of an
anti-inflammatory treatment with an α-syn-reducing treat-
ment has better disease-modifying effects than each treat-
ment alone in an animal model of MSA. These results
open the door for the design of more complex clinical trials
in which a carefully planned combination of therapies can
complement each other to target multiple aspects of the
pathology. However, more research will be necessary to
investigate how molecular pathways weave together to po-
tentially achieve synergism without eliciting unwanted dele-
terious effects in patients with neurodegenerative disorders.
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Additional file 1: V5 immunostaining confirms the expression of the
single-chain antibody CD5-D5-ApoB. (A) Representative images of V5
immunostaining (LV-CD5-D5-ApoB tag) in the neocortex of non-tg and
MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and
vehicle or lenalidomide. (B) Cell counts of V5-positive cells in in the
neocortex of non-tg and MBP-α-syn tg mice treated with LV-control or
LV-CD5-D5-ApoB, and vehicle or lenalidomide. (TIF 1365 kb)
Additional file 2: Morphological analysis of striatal microglia by Iba1
immunostaining. (A) Representative high-magnification images of Iba1
immunostaining in the striatum of non-tg and MBP-α-syn tg mice treated
with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. Inverted
images were used for quantification purposes. (B) Quantification of
microglial ramification as measured by the number of branches per cell.
(C) Microglial soma size as measured by the maximum soma diameter.
A minimum of 20 cells were quantified per animal. Results are presented as
average ± SEM. * p < 0.05, and *** p < 0.001 when comparing vehicle/LV-
control-treated non-tg mice to vehicle/LV-control-treated tg mice.
## p < 0.01 and ### p < 0.001 when comparing vehicle/LV-control-
treated tg mice to single or multi-treated tg mice. Scale bar = 20 μm.
(TIF 1825 kb)
Additional file 3: Analysis of striatal dendritic arborization by MAP2
immunostaining. (A) Representative high-magnification images of striatal
MAP2 immunostaining in the striatum of non-tg and MBP-α-syn tg mice
treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide.
Inverted images were used for quantification purposes. (B) Quantification
of dendritic density as measured by the percentage of MAP2 positive
area. (C) Quantification of dendritic arborization as measured by the
number of MAP2 positive branches per μm2. Results are presented as
average ± SEM. ** p < 0.01, and *** p < 0.001 when comparing vehicle/LV-
control-treated non-tg mice to vehicle/LV-control-treated tg mice.
#p < 0.05, ## p < 0.01 and ### p < 0.001 when comparing vehicle/LV-
control-treated tg mice to single or multi-treated tg mice. (TIF 1704 kb)
Additional file 4: Immunoblot analysis of oligodendroglial and myelination
markers. (A) Immunoblot analysis of the levels of MBP, CNPase and Olig2 in
non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB,
and vehicle or lenalidomide. Significant results of three mice per group are
shown. (B) Densitometric analysis of the levels of MBP, CNPase and Olig2 in
non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB,
and vehicle or lenalidomide. Results are presented as average ± SEM.
(TIF 1161 kb)
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